BioCentury
ARTICLE | Company News

FDA approves Ravicti

February 2, 2013 2:00 AM UTC

FDA approved an NDA for Ravicti glycerol phenylbutyrate from Hyperion Therapeutics Inc. (NASDAQ:HPTX) for the management of chronic urea cycle disorders in patients two years of age and older. The company plans to launch the drug in April, but did not disclose a price for the pre-prodrug of phenylacetic acid. Hyperion was up $0.38 to $16.01 on Friday. ...